BlinkLab (ASX:BB1) completed testing of the first patient in its digital diagnostic trial for autism at PriMED Clinical Research in Ohio, according to a Wednesday filing with the Australian bourse.
The study aims to validate the BlinkLab Dx1 neurological test as a diagnostic aid for clinicians in early assessment of developmental disorders, the filing said.
PriMED, along with North Shore Pediatric Therapy in Chicago, will participate in the initial study with 100 participants, with data set to be released in the third quarter of the year, per the filing.
Shares rose 7% in afternoon trade Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。